.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) Several brokerage firms have recently shared positive outlooks on prominent companies, highlighting potential growth opportunities and strategic advancements for the next 12 months.
Investec, Jefferies, and Nuvama have maintained 'Buy' ratings on UltraTech Cement, Apollo Hospitals, and Crompton Greaves Consumer Electricals Ltd, respectively, signaling strong upside potential for each stock.
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Investec on UltraTech Cement: Maintain Buy| Target Rs 12,450| LTP Rs 10420| Upside nearly 20%
Investec has maintained a 'Buy' rating on UltraTech Cement with a target price of Rs 12,450, indicating an upside of nearly 20% from its last traded price of Rs 10,420.
According to Investec, the market has overreacted to UltraTech's entry into the wire and cable segment.
They believe this segment offers healthy asset turns of approximately 4 times and EBIT margins ranging from 8% to 10%, making the recent stock correction unwarranted. However, they noted that a key risk to watch out for is the company's diversification into unrelated categories.
Despite this, Investec remains positive on UltraTech Cement's prospects and maintains a 'Buy' recommendation with the target price set at ₹12,450.
Also Read: 21% Ka Jhatka: UltraTech entry jolts cable & wire companies, profits on the line
Jefferies on Apollo Hospitals: Maintain Buy| Target Rs 7,900| LTP Rs 6187| Upside 27%
Jefferies has maintained a 'Buy' rating on Apollo Hospitals with a target price of Rs 7,900, indicating an upside of 27% from its last traded price of Rs 6,187.
A key debate revolves around the sustainability of 5-7% Average Revenue Per Occupied Bed (ARPOB) growth for Apollo amid the addition of new beds.
However, Jefferies believes that concerns over ARPOB are unwarranted, as bed additions for organized players are approximately 2% of their existing capacity.
These additions are expected to be phased over 3 to 5 years, minimizing any immediate impact on ARPOB growth.
Notably, Apollo Hospitals sustained an 8.3% ARPOB Compound Annual Growth Rate (CAGR) from FY11 to FY20, despite facing multiple headwinds during this period.
Based on these factors, Jefferies remains positive on Apollo Hospitals and maintains a 'Buy' recommendation with a target price of Rs 7,900.
Nuvama on Crompton Greaves Consumer Electricals Ltd: Maintain Buy| Target Rs 500| LTP Rs 324| Upside 54%
Nuvama has maintained a 'Buy' rating on Crompton Greaves Consumer Electricals Ltd with a target price of Rs 500, suggesting a potential upside of 54% from its last traded price of Rs 324.
The company has reiterated that it is progressing well on its Crompton 2.0 strategy, which focuses on achieving industry-leading Profit After Tax (PAT) growth, stabilizing its position in the lighting market, and turning around Butterfly Gandhimati Appliances.
Additionally, Crompton aims to capture a larger share of the premium fans market. The upcoming BEE 2.0 transition in January 2026 is expected to provide further market share gain opportunities for the company.
Crompton has also reported a positive start to the summer season. Furthermore, the company is exploring three to four new categories in solar pumps, and the reorganization of Butterfly Gandhimati has been completed with a new team in place, targeting mid-teens growth.
Based on these strategic moves and growth prospects, Nuvama remains optimistic about Crompton's future performance and maintains a 'Buy' recommendation with a target price of Rs500.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
Comments